Supplemental Fig. 1

1. Supplemental Fig. 1 T-cell proliferation (cps 3H thymidine) condition A - control condition D - DCs pre-incubated in lenalidomide condition C - T-cells pre-incubated in lenalidomide condition B - lenalidomide present during co-culture 1:10 1:30 1:100 1:300 1:1000 T-cells alone T-cells alone 1:1000

2. Supplemental Fig. 1 Lenalidomide increases T-cell proliferation after stimulation with allogeneic dendritic cells (allo-DCs) in a standard MLR by a direct effect on T-cells. In order to clarify if lenalidomide affects the antigen presenting cells, effector cells or both, the experiment was done using 4 different conditions: (A) T-cells and allo-DCs were co-cultured in a standard MLR without lenalidomide (■) . (B) 1 µM lenalidomide was added to the co-culture of T-cells and allo-DCs (×). (C) T-cells alone were “pre-treated” by 1 µM of lenalidomide in a culture for 5-7 days, washed, and co-cultured with allo-DCs in a lenalidomide-free media (▲). (D) DCs were matured in a media containing 1 µM of lenalidomide for 7 days, harvested, washed, and used to stimulate allogeneic T-cells in a lenalidomide-free media. (●)